Bilateral persistent placoid maculopathy following COVID-19 vaccines: real or coincidence?
dc.contributor.author | Ali, Esraa | |
dc.contributor.author | Chean, Chung Shen | |
dc.contributor.author | Kapoor, Bharat | |
dc.contributor.author | Kumar, Periyasamy | |
dc.date.accessioned | 2024-04-03T14:15:20Z | |
dc.date.available | 2024-04-03T14:15:20Z | |
dc.date.issued | 2023-08 | |
dc.identifier.citation | Chean, C. S., Ali, E., Kulkarni, P., Kapoor, B., & Kumar, P. (2023). Bilateral Persistent Placoid Maculopathy Following COVID-19 Vaccines: Real or Coincidence?. Ocular immunology and inflammation, 31(6), 1273–1278. https://doi.org/10.1080/09273948.2023.2170889 | en_US |
dc.identifier.other | 10.1080/09273948.2023.2170889 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12904/18457 | |
dc.description.abstract | COVID-19 vaccinations have been accompanied by reports of inflammatory uveitis. Herein, we report the first case of bilateral persistent placoid maculopathy (PPM) following COVID-19 vaccinations in a previously healthy 58-year-old man who presented with bilateral decrease in vision approximately 2 weeks after the second dose of AstraZenaca® ChAdOx1-S/nCoV-19 vaccine. Fundus examination revealed bilateral well-delineated whitish plaque-like macular lesions involving the fovea. Clinical and multimodal imaging findings were suggestive of PPM. Infective and autoimmune screen were all negative except for a raised MPO-ANCA. Medical review excluded systemic autoimmune and infectious diseases. Patient was monitored closely and his visual acuity improved and stabilised after a tapering regime of oral prednisolone. Mycophenolate mofetil was given as long-term steroid sparing immunosuppression. Our case demonstrated a likely localised autoimmune inflammatory response to the COVID-19 vaccine affecting choriocapillaris. Further research is needed to clarify the association between COVID-19 vaccines and inflammatory placoid lesions of the retina. | |
dc.description.uri | https://www.tandfonline.com/doi/full/10.1080/09273948.2023.2170889 | en_US |
dc.language.iso | en | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | persistent placoid maculopathy | en_US |
dc.subject | vaccine | en_US |
dc.title | Bilateral persistent placoid maculopathy following COVID-19 vaccines: real or coincidence? | en_US |
dc.type | Article | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |
rioxxterms.version | NA | en_US |
rioxxterms.versionofrecord | https://doi.org/10.1080/09273948.2023.2170889 | en_US |
rioxxterms.type | Journal Article/Review | en_US |
refterms.panel | Unspecified | en_US |
html.description.abstract | COVID-19 vaccinations have been accompanied by reports of inflammatory uveitis. Herein, we report the first case of bilateral persistent placoid maculopathy (PPM) following COVID-19 vaccinations in a previously healthy 58-year-old man who presented with bilateral decrease in vision approximately 2 weeks after the second dose of AstraZenaca® ChAdOx1-S/nCoV-19 vaccine. Fundus examination revealed bilateral well-delineated whitish plaque-like macular lesions involving the fovea. Clinical and multimodal imaging findings were suggestive of PPM. Infective and autoimmune screen were all negative except for a raised MPO-ANCA. Medical review excluded systemic autoimmune and infectious diseases. Patient was monitored closely and his visual acuity improved and stabilised after a tapering regime of oral prednisolone. Mycophenolate mofetil was given as long-term steroid sparing immunosuppression. Our case demonstrated a likely localised autoimmune inflammatory response to the COVID-19 vaccine affecting choriocapillaris. Further research is needed to clarify the association between COVID-19 vaccines and inflammatory placoid lesions of the retina. | en_US |
rioxxterms.funder.project | 94a427429a5bcfef7dd04c33360d80cd | en_US |